Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific cancers and these mutant proteins are proving to be excellent substrates for targeted therapies. This is the case for mutant EGFRdependent lung adenocarcinomas, where EGFR mutation testing is already being used to help guide treatment decisions. Here, we provide an overview of the biology of EGFR-targeted therapies and the clinical experience to date, the positive and negative predictors of response, pathologic correlates of EGFR-mutant status, testing methods to establish patient eligibility for these agents, and the basis for primary and secondary resistance.
Overview of EGFR biology and clinical correlations
Lung cancer is the leading cause of cancer deaths in both men and women in the United States. Over the past two decades, adenocarcinoma has replaced squamous cell carcinoma as the most common subtype of non-small cell lung cancer (NSCLC) in the United States.
The epidermal growth factor receptor (EGFR, HER-1/ErbB1) is a receptor tyrosine kinase (TK) of the ErbB family, which consists of four closely related receptors: HER-1/ErbB1, HER-2/neu/ErbB2, HER-3/ErbB3 and HER-4/ErbB4. Upon ligand binding and receptor homo-or hetero-dimerization and activation (phosphorylation), activated EGFR signals downstream to the PI3K/AKT and RAS/RAF/ MAPK pathways (Figure 1 ). These intracellular signaling pathways regulate key cellular processes such as proliferation and apoptosis.
The expression of EGFR by some lung cancers, the limited therapeutic options for advanced lung cancer, and the availability of new EGFR-targeted drugs led, in the early part of the decade, to clinical trials of small molecule EGFR TK inhibitors in unselected NSCLC patients. Although tumors in the vast majority of patients failed to respond, a minority showed dramatic tumor shrinkage accompanied by symptomatic improvement. Such responses were noted to be more common in East Asians, in women, and in patients with adenocarcinomas, especially those with areas of bronchioalveolar carcinoma (BAC). 1 These observations then led to three landmark 2004 studies that showed that the tumors that responded to the EGFR TK inhibitors (TKIs) gefitinib and erlotinib contain somatic mutations in the EGFR TK domain.
2-4 The two most common EGFR mutations are short in-frame deletions of exon 19 and a point mutation (CTG to CGG) in exon 21 at nucleotide 2573, that results in substitution of leucine by arginine at codon 858 (L858R). Together, these two types of mutations account for B90% of all EGFR mutations in NSCLC. Other recurrent but far less common EGFR mutations known to be associated with sensitivity to EGFR TKIs include the G719 mutations in exon 18 and the L861 mutations in exon 21. Screening for common EGFR mutations in patients with lung adenocarcinomas can now be performed in clinical molecular diagnostic laboratories to predict which patients will respond to EGFR TKIs. 5 It can be performed on archival material as well as on fine-needle biopsies. 6 Many other rare EGFR mutations have been reported in lung cancers, but the majority of such rare mutations are of much lesser clinical significance for three reasons. First, their association with response to EGFR TKIs has not been established. Second, many mutations that have been reported only once (ie, non-recurrent) may be technical artefacts arising from PCR and sequencing of DNA extracted from FFPE samples 7 (such artefacts can be guarded against by performing the PCR and sequencing in duplicate). Third, rare sequence alterations may actually represent rare germline polymorphisms because this possibility has not been excluded in all cases (to exclude this possibility, a normal DNA sample from the patient is sequenced).
In multiple recent prospective clinical trials of gefitinib or erlotinib, response rates of EGFR mutated cases range from 65 to 90%. [8] [9] [10] [11] [12] [13] Survival data from these studies are not yet mature, but in many instances, the median overall survival rates were 'not reached' at the time the data were reported. In most retrospective studies, patients with EGFR mutations and a response to gefitinib or erlotinib show a longer progression-free survival and a trend toward improved overall survival vs patients whose tumors have wild-type EGFR. Whether the longer survival observed in these studies is due to an intrinsically more favorable biology of lung cancers with EGFR mutations, or to the treatment with EGFR TKIs, is still somewhat controversial, but there is an emerging consensus that both factors are contributing to this longer overall survival. Indeed, a recent study found that EGFR mutations are associated with a modest but statistically significant survival benefit in patients with resectable lung adenocarcinoma (not treated with EGFR TKIs).
14 Thus, EGFR mutations may have both predictive and prognostic value.
Pathologic correlates of EGFR mutations
Historically, the practical utility of NSCLC as a clinical entity reflected the lack of distinct treatment regimens for the different histologic types encompassed by this term. With the advent of targeted therapy based on EGFR mutations in lung adenocarcinomas, it is evident that the histologic subtype of NSCLC should be explicitly reported. EGFR mutations are extremely rare in large cell carcinomas, small cell carcinomas, and pure squamous carcinomas, but have been reported in adenosquamous carcinomas. 15 Indeed, it may be that the very rare squamous carcinomas reported to harbor mutations were inadequately sampled adenosquamous carcinomas. There have also been two cases reported of EGFR-mutant small cell carcinoma preceded by an adenocarcinoma with the same mutation. 16, 17 Incidentally, another recent development that supports the retirement of the term 'NSCLC' is that bevacizumab (Avastin) is associated with a high risk of bleeding in squamous lung cancers 18 and therefore, has been approved only for use in 'non-squamous' NSCLCs.
Among adenocarcinomas, EGFR mutations are more prevalent in cases with BAC features. 19 Interestingly, the observation that BAC features are clinically significant was made before the discovery of EGFR mutations, based on the association of adenocarcinomas with BAC features with responses to EGFR TKIs. 1, 20 It should be noted that lung adenocarcinomas with a minor or major BAC component are not well delineated in the current WHO classification and therefore strict adherence to WHO categories may reduce the likelihood of making such observations. Microdissection studies have shown that EGFR mutations are present in BAC-like areas as well as more solid areas, suggesting that these are early events in these tumors. 19 This notion is reinforced by a recent report describing EGFR mutations in a third of lesions diagnosed as atypical adenomatous hyperplasia. 21 
EGFR mutation detection vs EGFR FISH/ CISH in the determination of EGFR status
There has been an ongoing debate regarding the most appropriate testing approach for establishing 'EGFR status' in lung adenocarcinomas, mutation analysis or gene copy number analysis (by FISH or CISH). [22] [23] [24] The relative importance of these two types of genetic alterations has been difficult to tease out because of their frequent co-occurrence. In our experience, among EGFR-mutated cases, approximately 50% also show increased EGFR gene copy number, and conversely, approximately 75% of cases with increased EGFR gene copy number show mutations. 25 These numbers vary in different series due to different scoring systems for gene copy number alterations and mutation detection techniques of different sensitivity (see below). There is now mounting evidence from multiple types of analyses supporting EGFR mutation status as a more rational and biologically relevant marker for treatment selection.
(1) Mutant EGFR is biologically linked to ligandindependent increased downstream signaling, unlike simple overexpression of native EGFR. (2) When both alterations are present, it is the mutated EGFR allele that is amplified preferentially. 25, 26 This suggests that in cases with both mutation and amplification, it is the biological advantage provided by the mutation that drives selection for copy number gains. (3) EGFR mutations are more closely linked to known risk factors (negative association with smoking) and other biological features (female sex, Asian origin) than is EGFR amplification. 25 (4) Response rates to EGFR TKIs are high in EGFRmutated cases regardless of EGFR copy number. In contrast, EGFR-amplified cases that lack mutations have very low response rates, in the order of 8%. 27 (5) In several recent studies, it has been shown that EGFR mutation status is a better predictor of outcome in patients treated with EGFR TKIs than EGFR copy number. [28] [29] [30] The failure of some earlier studies to detect survival benefits may have been due to the fact that they were statistically underpowered with respect to EGFR-mutant cases.
Part of the explanation for the survival benefit seen in EGFR amplified tumors apparently lacking EGFR mutations may be the following. Because FISH or CISH for EGFR amplification is a morphologic method (ie, non-neoplastic cells are not counted) whereas sequencing for mutation analysis is prone to false negatives due to excess nonneoplastic cells, it is likely that at least some EGFR-amplified cases reported to be mutationnegative based on direct sequencing have harbored mutations that would have been detected by more sensitive methods. Indeed, direct sequencing is prone to miss EGFR mutations (see below). Nonetheless, the situation remains complex because the subset of patients with tumors that lack detectable EGFR mutations but show increased EGFR copy number do show improved survival on EGFR TKIs despite the lack of radiologic response, compared to EGFR non-mutant tumors without EGFR amplification. 27, 29, 31 Clinical heterogeneity of EGFR mutations As mentioned above, some mutations are clearly associated with favorable responses to EGFR TKIs, whereas others are associated with poor responses or outright resistance to these same drugs. Thus, the relatively uncommon in-frame insertions in exon 20 are associated with primary resistance to EGFR TKIs. Interestingly, there may be differences even between the two main sensitivity mutations. Two retrospective studies have compared the outcome of EGFR TKI-treated patients based on the type of mutation present, namely exon 19 deletions or exon 21 L858R point mutation, and both found that the former group had a significantly better overall survival. 32, 33 Criteria for selecting cases for EGFR testing and the pathologist's role On the basis of the above considerations, the surgical pathologist's role in EGFR testing is to ensure that the testing is performed only in lung adenocarcinomas (or adenosquamous carcinomas), unless specifically requested by the oncologist. Among adenocarcinomas, some would suggest to exclude the mucinous subtype of BAC, as this special subtype is associated with KRAS mutations and not EGFR mutations, unlike non-mucinous BAC. 34, 35 Blocks or unstained sections submitted for DNA extraction and mutation analysis should be the most cellular available, preferably restricted to areas with 450% tumor cells. To ensure this, in many cases, further microdissection of the sections needs to be performed in the molecular diagnostic laboratory.
Importantly, EGFR IHC plays little or no role in selecting patients for EGFR mutation testing as it is only weakly correlated with the presence of mutations, if at all. Given this, it is not surprising that EGFR IHC positivity has generally been found of limited use in predicting response to EGFR TKIs. 36 Ironically, despite multiple publications questioning the significance of EGFR IHC, the Tarceva (erlotinib) product insert still emphasizes its importance.
Common methods for EGFR and KRAS mutation analysis
Initially, most large series used direct sequencing to detect these mutations. It is known that direct sequencing is likely to miss mutations when the tumor cells make up less than 25% of the sample. In some cases with EGFR mutations, this limit is somewhat lower because the mutant allele may be present in multiple copies per tumor cell (concurrent amplification). More recently, a number of studies of EGFR in lung cancer have employed more sensitive mutation detection techniques, including mutation-specific PCR assays, 37, 38 PCR with hybridization in real-time with mutation-specific fluorescent probes, 39, 40 single-strand conformational polymorphism, 35 denaturing high-performance liquid chromatography, 41, 42 peptide nucleic acidlocked nucleic acid PCR clamp 11 and more experimental techniques such as mass spectrometry and single molecule sequencing. 43 These have been recently reviewed. 44 Almost all such studies find a few cases with mutations that were missed by direct sequencing. The technical concern of detection sensitivity may be heightened for the secondary resistance mutations (see below).
Mutations in KRAS, BRAF and ERBB2 as predictors of primary resistance to EGFR inhibitors
It is now clear that mutations in EGFR, KRAS, BRAF and ERBB2 are essentially mutually exclusive in lung adenocarcinoma 19, [45] [46] [47] [48] [49] (Figure 2 ). This reflects the fact that they represent alternative ways of oncogenically activating some of the same downstream pathways, including the PI3K-AKT pathway and the MAPK pathway (Figure 1 ). ERBB2 mutations (in-frame insertions in exon 20; not amplification) occur in about 1-2% of adenocarcinomas and interestingly these, like EGFR-mutant tumors, often show BAC features, and occur preferentially in never smokers and women. 46, 47, 50 The presence of a KRAS mutation is both an adverse prognostic factor 14 and a predictor of failure to benefit from EGFR TKI therapy. [51] [52] [53] Indeed, in one study this went beyond a simple lack of response in that tumors with KRAS mutations did significantly worse when an EGFR TKI was added to their standard chemotherapy. 52 Most KRAS mutations, in contrast to EGFR mutations, appear smoking-related. 54 From these considerations, it should be evident that obtaining a comprehensive mutational profile of will eventually become clinically highly desirable, as each of these mutations has some impact on treatment selection. Aside from the fact that KRAS mutations are known, and BRAF and ERBB2 mutations are likely, to be associated with lack of response to EGFR TKIs, BRAF and ERBB2 mutations may also predict sensitivity to other targeted therapies. For instance, BRAF-mutant tumors may be especially sensitive to MEK inhibitors. 55 Finally, it should be noted that some rare primary EGFR mutations, such as exon 20 insertions, show poor responses to EGFR TKIs.
Secondary (acquired) resistance to EGFR inhibitors
In spite of dramatic tumor shrinkage in many patients with EGFR mutations, durable complete responses to EGFR TKIs remain uncommon. Acquired resistance to EGFR TKIs has been associated in at least 50% of cases with selection for a second EGFR mutation, most often T790M in exon 20 (rarely D761Y in exon 19).
13, [56] [57] [58] [59] The T790M secondary mutation may be underestimated for technical reasons, especially in cases with amplification of the EGFR allele with the first mutation. 23, 60, 61 A minority of patients whose tumors contain a T790M have not been exposed to EGFR TKIs, so this mutation may also be detectable at diagnosis. A family with multiple cases of NSCLC has been associated with germline transmission of this mutation, 62 but a subsequent screen of 237 lung cancer families for germline T790M mutations failed to find any additional cases. 63 In about 20% of patients with acquired resistance to gefitinib or erlotinib, tumor cells display amplification (thus far without mutations) of the MET oncogene at chromosome position 7q31. 64, 65 MET encodes a receptor TK implicated in the development, maintenance and progression of cancers in both animals and humans (reviewed in Birchmeier et al 66 ) . Interestingly, MET amplification appears to occur with or without T790M mutations. 65 As MET inhibitors and 'second-generation' EGFR inhibitors that can target T790M-bearing tumors enter into clinical use, pathologists may also need to optimize rapid testing methods for the T790M EGFR mutation and for MET amplification.
Prospects for IHC markers of EGFR and KRAS status
As discussed above, EGFR expression alone correlates poorly with the presence of activating EGFR mutations. In spite of this, the Tarceva package only mentions EGFR IHC for determining treatment eligibility. There has been intense interest in developing a better IHC-based marker for EGFR TKI treatment selection, that is, a marker that would have both good sensitivity and specificity for EGFR mutations. However, such a marker has so far proven elusive. The following have been investigated: phosphorylated EGFR or phosphorylated downstream signaling proteins such as phospho-AKT, phospho-ERK/MAPK and phospho-S6. 29, [67] [68] [69] [70] In some of these studies, expression of phospho-AKT appeared to correlate with response to EGFR TKIs. Adenocarcinomas without evidence of epithelial-to-mesenchymal transition (ie, better differentiated ones) have also been reported to be more likely to respond and they can be identified by staining for E-cadherin.
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Conclusion
The clinical development of EGFR TKIs in lung cancer and the subsequent discovery of activating mutations in EGFR as the molecular basis for increased tumor sensitivity to these drugs have revolutionized lung cancer management. However, the field continues to rapidly evolve. At present, EGFR mutation analysis represents the most accurate available test for prediction of response to EGFR TKIs, and many studies support its usefulness in predicting survival benefit as well. Combining mutation analysis with EGFR FISH or CISH may provide additional clinically useful information. Some key areas of further work in the practical molecular pathology of EGFR-mutant tumors include defining optimal mutation detection techniques, identifying the key mutations that need to be tested for selection of first or second generation EGFR TKIs, developing cost-effective approaches to testing for a growing number of clinically relevant mutations in EGFR and associated genes, and identifying robust surrogate IHC markers of EGFR status. If other subtypes of adenocarcinoma prove to have molecular aberrations that could direct targeted therapy, the current paradigm of EGFR-mutant lung cancers will be extended. Finally, it should be noted that, in several respects, the targeted therapy of lung adenocarcinoma compares favorably with that of breast carcinoma (Table 1) . 
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